CLDX
Celldex Therapeutics Inc
NASDAQ · Biotechnology
$23.76
+1.18 (+5.23%)
Income Statement
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Revenue | 7.24M | 6.31M | 588.88M | 613.37M | 463.47M |
| Net Income | -162,900,874 | -127,798,802 | -4,307,781 | -4,777,656 | -4,595,403 |
| EPS | — | — | — | — | — |
| Profit Margin | -2,248.8% | -2,136.3% | -0.7% | -0.8% | -1.0% |
| Rev Growth | +14.7% | +14.7% | -8.7% | +23.6% | +12.7% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| Total Debt | 0 | 0 | 596.71M | 650.05M | 724.29M |
| Total Equity | — | — | 650.53M | 684.23M | 651.26M |
| D/E Ratio | — | — | 0.92 | 0.95 | 1.11 |
Cash Flow
| FY 2026 | FY 2025 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|---|
| EBITDA | -198,026,064 | -163,986,018 | -9,082,544 | -9,452,277 | -7,129,969 |
| Free Cash Flow | — | — | -4,299,158 | -4,482,621 | -2,547,498 |